Palisade Bio (PALI) Assets Average (2011 - 2026)
Palisade Bio (PALI) posted quarterly Assets Average of $133.8 million for Q1 2026, up 1303.56% year-over-year from $9.5 million in Q1 2025, and up 89.4% quarter-over-quarter from $70.7 million in Q4 2025.
Palisade Bio (PALI) Assets Average (2011 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Assets Average for 16 consecutive years, with $133.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 1303.56% year-over-year to $133.8 million; the TTM figure through Mar 2026 stood at $133.8 million (up 1303.56% YoY), while the FY2025 annual figure was $72.6 million, up 482.48% from the prior year.
- Assets Average advanced to $133.8 million in Q1 2026 per PALI's latest filing, from $70.7 million in the prior quarter.
- Across five years, Assets Average topped out at $133.8 million in Q1 2026 and bottomed at $6.8 million in Q3 2025.
- Historically, Assets Average has averaged $22.8 million across 5 years, with a median of $12.8 million in 2024.
- Annual changes were most pronounced in 2025 — Assets Average plunged 41.79% — and 2026, when it soared 1303.56%.
- Palisade Bio's Assets Average stood at $16.0 million in 2022, then fell by 2.84% to $15.6 million in 2023, then sank by 35.04% to $10.1 million in 2024, then surged by 599.04% to $70.7 million in 2025, then jumped by 89.4% to $133.8 million in 2026.
- Business Quant data shows PALI's Assets Average at $133.8 million in Q1 2026, $70.7 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 130.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.32 Mn |
| Mar 31, 2026 | 133.83 Mn |
| Dec 31, 2025 | 70.66 Mn |
| Sep 30, 2025 | 6.82 Mn |
| Jun 30, 2025 | 7.43 Mn |
| Mar 31, 2025 | 9.54 Mn |
| Dec 31, 2024 | 10.11 Mn |
| Sep 30, 2024 | 11.10 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Mar 31, 2024 | 13.35 Mn |
| Dec 31, 2023 | 15.56 Mn |
| Sep 30, 2023 | 17.68 Mn |
| Jun 30, 2023 | 16.78 Mn |
| Mar 31, 2023 | 15.51 Mn |
| Dec 31, 2022 | 16.01 Mn |
| Sep 30, 2022 | 12.04 Mn |
| Jun 30, 2022 | 8.08 Mn |
| Mar 31, 2022 | 10.43 Mn |
| Dec 31, 2021 | 14.39 Mn |
| Sep 30, 2021 | 15.61 Mn |